🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for FLT3 Gene Mutation

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML NCT05024552Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Gilteritinib, Vyxeos A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease NCT05886049Phase 123 sites📍 Orange📍 Sacramento📍 Aventura National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Daunorubicin MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib NCT07463651Phase 32 sites📍 Suzhou📍 Shanghai The First Affiliated Hospital of Soochow University · Tests: Gilteritinib, Sorafenib A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants NCT07162116Phase 11 site📍 Zibo Shijiazhuang Yiling Pharmaceutical Co. Ltd · Tests: XY0206, Moxifloxacin (400 mg), XY0206 Placebo Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia NCT06366789Phase 123 sites📍 Los Angeles📍 San Francisco📍 Atlanta Lomond Therapeutics Holdings, Inc. · Tests: ZE46-0134 Revumenib in Combination With 7+3 + Midostaurin in AML NCT06313437Phase 12 sites📍 New Haven📍 Boston Richard Stone, MD · Tests: Revumenib, Midostaurin, Cytarabine, Daunorubicin ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT05010122Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine and Cedazuridine, Gilteritinib, Venetoclax Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm NCT04140487Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Azacitidine, Gilteritinib, Venetoclax Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia NCT06022003Phase 220 sites📍 Amiens📍 Angers📍 Clamart French Innovative Leukemia Organisation · Tests: AzaCITIDine Oral Tablet, Xospata Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML NCT07259707Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: GVA + HDAC Consolidation & Gilteritinib Maintenance Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) NCT04385290Phase 1, Phase 221 sites📍 München📍 Essen📍 Aachen Technische Universität Dresden · Tests: MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, MAGNOLIA-trial: Midosta… SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation NCT06222580Phase 14 sites📍 Chapel Hill📍 Columbus📍 Philadelphia Uma Borate · Tests: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, Revumenib, Echocardiography Test HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia NCT07137637Phase 11 site📍 Tianjin Hangzhou Polymed Biopharmaceuticals, Inc. · Tests: HPB-092 tablet The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation NCT06561880Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Venetoclax, Cytarabine, Gilteritinib, Azacitadine (AZA)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy